Pembrolizumab
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial Timeline
Nov 14, 2018 → Jul 1, 2029
NCT ID
NCT03546582About Pembrolizumab
Pembrolizumab is a phase 2 stage product being developed by Merck for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is active. This product is registered under clinical trial identifier NCT03546582. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC).
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma (HNSCC) were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02083484 | Pre-clinical | Completed |
| NCT07302347 | Phase 1/2 | Recruiting |
| NCT07089992 | Phase 2 | Recruiting |
| NCT07007273 | Phase 2 | Recruiting |
| NCT04569461 | Phase 2 | Withdrawn |
| NCT05815927 | Phase 3 | Recruiting |
| NCT05852223 | Phase 2 | Recruiting |
| NCT05879120 | Phase 2 | Withdrawn |
| NCT06004336 | Phase 2 | Recruiting |
| NCT05496036 | Phase 2 | Recruiting |
| NCT05131919 | Phase 2 | Active |
| NCT05197322 | Phase 2 | Recruiting |
| NCT05406713 | Phase 2 | Active |
| NCT05025813 | Phase 2 | Recruiting |
| NCT06413095 | Phase 1 | Completed |
| NCT05191472 | Phase 2 | Terminated |
| NCT05204160 | Phase 2 | Withdrawn |
| NCT04575961 | Phase 2 | Active |
| NCT04417166 | Phase 2 | Recruiting |
| NCT05188508 | Phase 2 | Recruiting |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)